Lynn Tetrault Acquires Shares in Rhythm Pharmaceuticals

Lynn Tetrault made a significant move by purchasing 37,000 shares of Rhythm Pharmaceuticals, Inc. (NasdaqGM:RYTM) on June 22, 2026. Each share was bought at $28.27, bringing the total transaction to approximately $1.05 million. This insider transaction was not part of a pre-planned trading plan.

Insider Buying and Selling at Rhythm Pharmaceuticals, Inc.

Lynn Tetrault's recent purchase adds to a series of insider activities at Rhythm Pharmaceuticals. On the same day, she also sold 37,000 shares at an average price of $100.32. Earlier, on May 18, 2026, Hunter Smith, the Chief Financial Officer, bought 3,000 shares at $17.87. Similarly, Christopher Paul German, the Corporate Controller & CAO, acquired 4,442 shares at $42.17 on May 15, 2026.

Other Institutional Activity in Rhythm Pharmaceuticals

RA Capital Management, L.P. holds a significant position in Rhythm Pharmaceuticals with 6,666,837 shares valued at approximately $579.8 million, maintaining its holdings without changes. BlackRock, Inc., another major investor, reduced its stake by 60,183 shares, ending with 6,237,151 shares worth about $542.4 million, marking a 1.0% decrease. Similarly, Primecap Management Co/CA/ trimmed its holdings by 61,160 shares to a total of 3,417,509 shares valued at $297.2 million, a 1.8% reduction. Meanwhile, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions with 3,040,718 and 2,967,825 shares, respectively.

Rhythm Pharmaceuticals, Inc. Stock Down 0.9%

Shares of Rhythm Pharmaceuticals traded near $106.19 on Thursday. The company has a market cap of about $6.95 billion and a forward P/E ratio that isn't meaningful due to its lack of profitability. With a beta of 1.923, the stock has seen a 52-week low of $60.8 and a high of $122.2. Its 50-day moving average is $88.36, while the 200-day moving average is $97.77. The company maintains a strong liquidity position with a current ratio of 4.168 and a quick ratio of 3.632, though it has a debt-to-equity ratio of 47.264.

Analysts Set New Price Targets

Analysts have been active in setting price targets for Rhythm Pharmaceuticals. On June 16, 2026, Canaccord Genuity maintained its 'buy' rating with a price target of $151. Wells Fargo also upheld its 'buy' rating on June 15, with a target of $155. The consensus among analysts remains strong, with a mean price target of $139.47 and a 'strong buy' recommendation from 15 analysts.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., headquartered in Boston, Massachusetts, is a biopharmaceutical company focusing on rare neuroendocrine diseases. Its main product, IMCIVREE (setmelanotide), targets various forms of obesity related to genetic deficiencies. The company is engaged in multiple clinical trials, including Phase 3 trials for hypothalamic obesity and Phase 2 trials for other obesity-related conditions. Founded in 2008, Rhythm Pharmaceuticals aims to address unmet needs in the field of rare diseases.

Bottom Line

Lynn Tetrault's purchase of Rhythm Pharmaceuticals shares is a notable insider move, reflecting potential confidence in the company's direction. Investors closely monitor such insider actions as part of their analysis, though they are backward-looking and may not indicate future stock performance. With ongoing clinical trials and a focus on rare diseases, Rhythm Pharmaceuticals remains a company of interest in the biopharmaceutical sector.